127 related articles for article (PubMed ID: 26970129)
21. Ductal carcinoma in situ, complexities and challenges.
Leonard GD; Swain SM
J Natl Cancer Inst; 2004 Jun; 96(12):906-20. PubMed ID: 15199110
[TBL] [Abstract][Full Text] [Related]
22. A phase II chemoprevention trial design to identify surrogate endpoint biomarkers in breast cancer.
Dhingra K
J Cell Biochem Suppl; 1995; 23():19-24. PubMed ID: 8747374
[TBL] [Abstract][Full Text] [Related]
23. Tamoxifen reduces breast cancer rate in at-risk healthy women by nearly a third, finds study.
Kmietowicz Z
BMJ; 2014 Dec; 349():g7596. PubMed ID: 25500812
[No Abstract] [Full Text] [Related]
24. Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial.
Fisher B; Dignam J; Wolmark N; Wickerham DL; Fisher ER; Mamounas E; Smith R; Begovic M; Dimitrov NV; Margolese RG; Kardinal CG; Kavanah MT; Fehrenbacher L; Oishi RH
Lancet; 1999 Jun; 353(9169):1993-2000. PubMed ID: 10376613
[TBL] [Abstract][Full Text] [Related]
25. Biological response to hormonal manipulation in oestrogen receptor positive ductal carcinoma in situ of the breast.
Boland GP; McKeown A; Chan KC; Prasad R; Knox WF; Bundred NJ
Br J Cancer; 2003 Jul; 89(2):277-83. PubMed ID: 12865917
[TBL] [Abstract][Full Text] [Related]
26. Chemoprevention of Breast Cancer by Transdermal Delivery of α-Santalol through Breast Skin and Mammary Papilla (Nipple).
Dave K; Alsharif FM; Islam S; Dwivedi C; Perumal O
Pharm Res; 2017 Sep; 34(9):1897-1907. PubMed ID: 28589445
[TBL] [Abstract][Full Text] [Related]
27. ACP Journal Club. Tamoxifen for 5 years reduced 16-year risk for breast cancer in women at increased risk.
Parsons H; Stearns V
Ann Intern Med; 2015 May; 162(10):JC11. PubMed ID: 25984872
[No Abstract] [Full Text] [Related]
28. Aromatase inhibitors and breast cancer prevention.
Litton JK; Arun BK; Brown PH; Hortobagyi GN
Expert Opin Pharmacother; 2012 Feb; 13(3):325-31. PubMed ID: 22242911
[TBL] [Abstract][Full Text] [Related]
29. Postoperative Tamoxifen for ductal carcinoma in situ: Cochrane systematic review and meta-analysis.
Staley H; McCallum I; Bruce J
Breast; 2014 Oct; 23(5):546-51. PubMed ID: 25023044
[TBL] [Abstract][Full Text] [Related]
30. Salvage treatment for local recurrence after breast-conserving surgery and radiation as initial treatment for mammographically detected ductal carcinoma in situ of the breast.
Solin LJ; Fourquet A; Vicini FA; Haffty B; Taylor M; McCormick B; McNeese M; Pierce LJ; Landmann C; Olivotto IA; Borger J; de La Rochefordiere A; Schultz DJ
Cancer; 2001 Mar; 91(6):1090-7. PubMed ID: 11267953
[TBL] [Abstract][Full Text] [Related]
31. Anastrozole versus tamoxifen in postmenopausal women with ductal carcinoma in situ undergoing lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial.
Margolese RG; Cecchini RS; Julian TB; Ganz PA; Costantino JP; Vallow LA; Albain KS; Whitworth PW; Cianfrocca ME; Brufsky AM; Gross HM; Soori GS; Hopkins JO; Fehrenbacher L; Sturtz K; Wozniak TF; Seay TE; Mamounas EP; Wolmark N
Lancet; 2016 Feb; 387(10021):849-56. PubMed ID: 26686957
[TBL] [Abstract][Full Text] [Related]
32. Initiation of and adherence to tamoxifen and aromatase inhibitor therapy among elderly women with ductal carcinoma in situ.
Zhao H; Hei N; Wu Y; Chan W; Lei X; Cameron C; Chang S; Chavez-MacGregor M; Giordano SH
Cancer; 2017 May; 123(6):940-947. PubMed ID: 27780311
[TBL] [Abstract][Full Text] [Related]
33. Intraductal Therapy in Breast Cancer: Current Status and Future Prospective.
Kuang XW; Liu JH; Sun ZH; Sukumar S; Sun SR; Chen C
J Mammary Gland Biol Neoplasia; 2020 Jun; 25(2):133-143. PubMed ID: 32577880
[TBL] [Abstract][Full Text] [Related]
34. Postmenopausal women with DCIS post-mastectomy: a potential role for aromatase inhibitors.
Chlebowski RT; Col N
Breast J; 2012; 18(4):299-302. PubMed ID: 22681627
[TBL] [Abstract][Full Text] [Related]
35. Psychological distress and physical health in the year after diagnosis of DCIS or invasive breast cancer.
Lauzier S; Maunsell E; Levesque P; Mondor M; Robert J; Robidoux A; Provencher L
Breast Cancer Res Treat; 2010 Apr; 120(3):685-91. PubMed ID: 19653097
[TBL] [Abstract][Full Text] [Related]
36. Alternate dosing schedules for cancer chemopreventive agents.
Lazzeroni M; DeCensi A
Semin Oncol; 2016 Feb; 43(1):116-122. PubMed ID: 26970130
[TBL] [Abstract][Full Text] [Related]
37. Tamoxifen added to radiotherapy and surgery for the treatment of ductal carcinoma in situ of the breast: a meta-analysis of 2 randomized trials.
Petrelli F; Barni S
Radiother Oncol; 2011 Aug; 100(2):195-9. PubMed ID: 21411161
[TBL] [Abstract][Full Text] [Related]
38. Responsiveness of adjacent ductal carcinoma in situ and changes in HER2 status after neoadjuvant chemotherapy/trastuzumab treatment in early breast cancer--results from the GeparQuattro study (GBG 40).
von Minckwitz G; Darb-Esfahani S; Loibl S; Huober J; Tesch H; Solbach C; Holms F; Eidtmann H; Dietrich K; Just M; Clemens MR; Hanusch C; Schrader I; Henschen S; Hoffmann G; Tiemann K; Diebold K; Untch M; Denkert C
Breast Cancer Res Treat; 2012 Apr; 132(3):863-70. PubMed ID: 21667238
[TBL] [Abstract][Full Text] [Related]
39. Chemoprevention of breast cancer: implications for postmenopausal women.
Fabian CJ; Kimler BF
Drugs Aging; 2002; 19(1):43-78. PubMed ID: 11929326
[TBL] [Abstract][Full Text] [Related]
40. Novel iontophoretic administration method for local therapy of breast cancer.
Komuro M; Suzuki K; Kanebako M; Kawahara T; Otoi T; Kitazato K; Inagi T; Makino K; Toi M; Terada H
J Control Release; 2013 Jun; 168(3):298-306. PubMed ID: 23562634
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
